Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies

Cancer Treatment Reviews

Volumn 34, Issue SUPPL. 1, 2008, Pages

  Coleman, Robert E ^a   Body, Jean Jacques ^b   Gralow, Julie R ^c   Lipton, Allan ^d  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitor; Bisphosphonate; Breast cancer; Cancer treatment induced bone loss; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; EXEMESTANE; FULVESTRANT; GOSERELIN; HORMONE RECEPTOR; IBANDRONIC ACID; LETROZOLE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ALGORITHM; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE NECROSIS; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIFFERENTIAL DIAGNOSIS; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY CANCER; ENDOMETRIUM CANCER; FRAGILITY FRACTURE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; JAW DISEASE; LIFESTYLE MODIFICATION; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; PHARMACODYNAMICS; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT PLANNING;

EID: 44649083063     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.03.005     Document Type: Review

References (76)

1. American Cancer Society. Breast Cancer Facts & Figures 2007-2008. Atlanta: American Cancer Society Inc.; 2007.
2. Cheung K.L. Endocrine therapy for breast cancer: an overview. Breast 16 (2007) 327-343
3. Carpenter R., and Miller W.R. Role of aromatase inhibitors in breast cancer. Br J Cancer 93 Suppl. 1 (2005) S1-S5
4. ® (letrozole tablets) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
5. ® (exemestane tablets) [package insert]. New York: Pharmacia & Upjohn Co., Division of Pfizer Inc.; 2005.
6. ® (anastrozole) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2005.
7. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
8. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
9. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
10. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
11. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA 17. J Natl Cancer Inst 97 (2005) 1262-1271
12. Geisler J., Haynes B., Anker G., Dowsett M., and Lonning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20 (2002) 751-757
13. Geisler J., King N., Anker G., et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4 (1998) 2089-2093
14. Perez E.A. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 18 Suppl. 8 (2007) viii26-viii35
15. Cummings S.R., Browner W.S., Bauer D., et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 339 (1998) 733-738
16. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., and Adams J.E. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21 (2006) 1215-1223
17. Warming L., Hassager C., and Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 13 (2002) 105-112
18. Zhang H.C., Kushida K., Atsumi K., Kin K., and Nagano A. Effects of age and menopause on spinal bone mineral density in Japanese women: a ten-year prospective study. Calcif Tissue Int 70 (2002) 153-157
19. Eastell R., and Adams J. Results of the 'Arimidex' (anastrozole, A), tamoxifen (T), alone or in combination (C) (ATAC) trial: effects on bone mineral density (BMD) and bone turnover (ATAC Trialists' Group). Ann Oncol 13 Suppl. 5 (2002) 32 [abstract 113PD]
20. Shapiro C.L., Manola J., and Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19 (2001) 3306-3311
21. Gnant M.F.X., Mlineritsch B., Luschin-Ebengreuth G., et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25 (2007) 820-828
22. Albrand G., Munoz F., Sornay-Rendu E., DuBoeuf F., and Delmas P.D. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 32 (2003) 78-85
23. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27 (2001) 165-176
24. Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 33 Suppl. 7 (2006) 13-17
25. Bundred N., Campbell I., Coleman R., et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZOFAST study). Eur J Cancer Suppl 4 (2006) 48 [abstract 12]
26. Coleman R.E., Banks L.M., Girgis S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8 (2007) 119-127
27. Lipton A., Gnant M., and Aapro M. Managing aromatase inhibitor-associated bone loss in breast cancer. Women's Health 3 (2007) 441-448
28. McCloskey E.V., Hannon R.A., Lakner G., et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 43 (2007) 2523-2531
29. Goss P.E., Hadji P., Subar M., Abreu P., Thomsen T., and Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 9 (2007) R52 [Epub ahead of print]
30. Harper-Wynne C., Ross G., Sacks N., et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 11 (2002) 614-621
31. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24 (2006) 3629-3635
32. Lonning P.E., Geisler J., Krag L.E., et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23 (2005) 5126-5137
33. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000;17:1-45.
34. Pfeilschifter J., and Diel I.J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18 (2000) 1570-1593
35. Hadji P, Aapro M, Brufsky A, Tubiana-Hulin M, Guise T, Body JJ. Practical guidelines for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer. Ann Oncol, in press.
36. Palmieri C., MacGregor T., Girgis S., and Vigushin D. Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol 59 (2006) 1334-1336
37. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
38. Holmberg L., and Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 363 (2004) 453-455
39. Christodoulakos G.E., Lambrinoudaki I.V., and Botsis D.C. The cardiovascular effects of selective estrogen receptor modulators. Ann NY Acad Sci 1092 (2006) 374-384
40. Howell S.J., Johnston S.R., and Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab 18 (2004) 47-66
41. Whannel KJ, McLellan A, Wilson CR, Doughty JC. The need for DXA assessment of breast cancer patients following 5 years tamoxifen prior to starting an aromatase inhibitor. In: Presented at 29th annual san antonio breast cancer symposium; December 14-17, 2006; San Antonio, TX [abstract 4046].
42. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
43. ® (fulvestrant) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2004.
44. Lea C.K., and Flanagan A.M. Ovarian androgens protect against bone loss in rats made oestrogen deficient by treatment with ICI 182,780. J Endocrinol 160 (1999) 111-117
45. Agrawal A., Hannon R.A., Cheung K.L., Eastell R., and Robertson J.F. Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant. J Clin Oncol 24 Suppl. (2006) 47s [abstract 680]
46. Saarto T., Blomqvist C., Valimaki M., Makela P., Sarna S., and Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 75 (1997) 602-605
47. Saarto T., Blomqvist C., Valimaki M., Makela P., Sarna S., and Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15 (1997) 1341-1347
48. Vehmanen L., Saarto T., Risteli J., Risteli L., Blomqvist C., and Elomaa I. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 87 (2004) 181-188
49. Delmas P.D., Balena R., Confravreux E., Hardouin C., Hardy P., and Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15 (1997) 955-962
50. Eastell R., Van Poznak C.H., Hannon R.A., et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. J Bone Miner Res 22 Suppl. 1 (2007) S113 [abstract 300]
51. Van Poznak CH, Hannon RA, Clack G, et al. Markers of bone metabolism in postmenopausal women with hormone receptor-positive early breast cancer: SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE). In: Presented at 2007 ASCO breast cancer symposium; September 7-8, 2007; San Francisco, CA [abstract 156].
52. Waltman N.L., Twiss J.J., Ott C.D., et al. Testing an intervention for preventing osteoporosis in postmenopausal breast cancer survivors. J Nurs Scholarsh 35 (2003) 333-338
53. Sawka A.M., Ioannidis G., Papaioannou A., et al. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?. J Obstet Gynaecol Can 27 (2005) 759-764
54. Yamada K., Kohno N., Endoh K., et al. The role of bisphosphonates and bone health issues in Japanese breast cancer patients: efficacy of alendronate with aromatase inhibitors. J Clin Oncol 24 Suppl. (2006) 590s [abstract 10777]
55. Lester J.E., Gutcher S.A., Ellis S.P., et al. Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: one-year results from the ARIBON study. J Clin Oncol 25 Suppl. (2007) 16s [abstract 553]
56. Reginster J.Y., Rabenda V., and Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38 Suppl. 1 (2006) S2-S6
57. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
58. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid-new results from ABCSG-12. In: Presented at 30th annual san antonio breast cancer symposium; December 13-17, 2007; San Antonio, TX [abstract 26].
59. Brufsky A, Bosserman L, Caradonna R, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. In: Presented at 30th annual san antonio breast cancer symposium; December 13-17, 2007; San Antonio, TX [abstract 27].
60. Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25 (2007) 829-836
61. Bundred N, Campbell I, Coleman R. Zoledronic acid in the prevention of cancer treatment induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer. Cancer Epidemiol Biomarkers Prev, in press.
62. De Boer R., Eidtmann H., Lluch A., et al. The ZO-FAST trial: Zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24-month BMD results. Breast Cancer Res Treat 106 Suppl. 1 (2007) S36 [abstract 501]
63. Schenk N., Llombart A., Frassoladti A., et al. The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let). Eur J Cancer 5 (2007) 186 [abstract 2008]
64. US National Institutes of Health. Risedronate in improving bone mineral density and bone health in postmenopausal women with ductal carcinoma in situ enrolled in clinical trial CRUK-IBIS-II-DCIS. Available at: .
65. US National Institutes of Health. Effect of bisphosphonate on bone loss in postmenopausal women with breast cancer initiating aromatase inhibitor therapy. Available at: .
66. US National Institutes of Health. Bisphosphonate and anastrozole trial-bone maintenance algorithm assessment. Available at: .
67. US National Institutes of Health. Safety/efficacy of letrozole monotherapy or in combination with zoledronic acid as extended adjuvant treatment of postmenopausal patients with primary breast cancer. Available at: .
68. US National Institutes of Health. Effectiveness of zoledronic acid in the prevention of osteoporosis in early breast cancer patients receiving letrozole. Available at: .
69. US National Institutes of Health. HOBOE: a study of hormonal adjuvant treatment effect on bone mineral density in early breast cancer patients. Available at: .
70. US National Institutes of Health. The safety and efficacy of zoledronic acid in the prevention of cancer therapy induced bone loss. Available at: .
71. Ellis S, Bone HG, Chlebowski RT, et al. A phase 3 study of the effect of denosumab therapy on bone mineral density in women receiving aromatase inhibitors for nonmetastatic breast cancer. In: Presented at 30th annual san antonio breast cancer symposium; December 13-17, 2007; San Antonio, TX [abstract 47].
72. Weitzman R., Sauter N., Eriksen E.F., et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62 (2007) 148-152
73. Mavrokokki T., Cheng A., Stein B., and Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 (2007) 415-423
74. Conte P., and Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9 Suppl. 4 (2004) 28-37
75. National Comprehensive Cancer Network Inc. Clinical Practice Guidelines in Oncology™: Breast Cancer. V.2.2007. Available at: .
76. Body J.J., Bergmann P., Boonen S., et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporos Int 18 (2007) 1439-1450